Abstract 1555P
Background
Approved for 17 cancers in Japan, use of IO therapy has steadily increased since 2014. For four IO therapies (nivolumab, pembrolizumab, atezolizumab, and durvalumab), we modeled life years saved (LYS), the social value of those LYS, and how that value distributes across manufacturers and society for six, high-burden, advanced/recurrent cancers (non-small cell lung cancer, renal, head and neck squamous cell carcinoma, gastric, urothelial, and endometrial) in Japan.
Methods
A model of IO therapy treatment for six cancers estimated LYS and their monetized value. Per-person survival gains were estimated using digitized overall survival curves relative to a prior treatment standard reported by landmark clinical trials supporting IO therapy approval for each cancer. These per-person gains were scaled to the Japanese population using data from a nationally representative hospital treatment database and monetized to total social value using published estimates of the value of a statistical life year based upon human capital and willingness to pay approaches. Manufacturer and societal shares using time-varying drug and administrative costs were calculated. A 5-year timeframe beginning Jan 1, 2017, comprised our base-case. The impact of analytic timeframe, rates of IO therapy utilization, time on treatment, and treatment efficacy were explored in univariate sensitivity analyses.
Results
The base-case indicated the four IO therapies resulted in 8,851 LYS among patients with the six modeled cancers for a net social value of ¥244B (benefit less treatment costs) of which 86.5% (¥211B) was classified as social surplus (share of value to patients and other parts of society) versus 13.5% (¥33B) to manufacturers (manufacturer share). Estimates were most sensitive to analytic timeframe. Over a 10-year timeframe, an additional 28,715 patients would receive IO therapy for these cancers resulting in 17,863 additional LYS for a ¥509B increase in net social value. While ¥94B additional treatment costs are incurred, the manufacturer share of social value decreased to 4.9%.
Conclusions
In Japan among six high-burden cancers, treatment with four IO therapies has generated substantial social value, and the societal share of that value has increased over time and with increased therapy use.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Merck Sharp & Dohme LLC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10